Atezolizumab

SAN DIEGO, Oct. 14, 2026 /PRNewswire/ -- Equity Insider News Commentary - Global spending on cancer medicines reached $252 billion in 2024 and is forecast to exceed $400 billion by 2028, according to the IQVIA Institute, with the United States accounting for roughly 46% of the total. The pace of new treatments has picked up with it: about 150 new active substances entered the U.S. oncology market between 2015 and 2024, and launch activity in 2020 to 2024 ran nearly 40% ahead of the prior five years. Active Companies from around the markets with current developments this week include: Oncolytics Biotech, Inc. (NASDAQ: ONCY), Revolution Medicines, Inc. (NASDAQ: RVMD), Eli Lilly and Company (NYSE: LLY), Genmab A/S (NASDAQ: GMAB), Exelixis, Inc. (NASDAQ: EXEL). The past several weeks have shown how quickly that pipeline is turning into new standards of care. On August 26, the U.S. Food and Drug Administration approved the first broad RAS-targeted medicine for metastatic pancreatic cancer, one of the hardest-to-treat solid tumors. In the first two weeks of October, regulators approved a new first-line use for a blood cancer therapy, a first-line maintenance treatment for HER2-positive metastatic breast cancer and a checkpoint inhibitor combination for stage III mismatch repair-deficient colon cancer, while two large Phase 3 trials in lymphoma and multiple myeloma reported positive topline results. Gastrointestinal cancers are drawing a growing share of that attention. RAS mutations drive many pancreatic and colorectal tumors, and for years they were considered nearly impossible to drug. Colorectal cancer adds a second challenge: most metastatic cases are microsatellite stable, a form that has generally responded poorly to the checkpoint inhibitors that transformed treatment in other cancers. Companies are attacking the problem from several directions, with targeted RAS inhibitors, new drug combinations and therapies designed to make tumors more visible to the immune system. Investors will get a fresh look at much of this work soon. The European Society for Medical Oncology holds its 2026 Congress in Madrid from October 23 to 27, one of the largest annual meetings for new cancer data, and two of the companies below have pointed to colorectal cancer updates before year-end. Oncolytics Biotech, Inc. (NASDAQ: ONCY) Oncolytics is developing pelareorep, an intravenously delivered immunotherapy designed to turn immunologically "cold" tumors "hot," and colorectal cancer is now at the center of its clinical plans. On September 28 the company reported accelerating enrollment in REO 033, a randomized study in second-line RAS-mutant, microsatellite-stable metastatic colorectal cancer that compares pelareorep plus FOLFIRI and bevacizumab with FOLFIRI and bevacizumab alone. Part A is expected to randomize about 60 patients, with objective response rate as the primary endpoint and progression-free survival, overall survival, safety and biomarkers as additional endpoints. The study builds on REO 022, a smaller non-randomized trial in which the same pelareorep combination produced a 33% objective response rate, median progression-free survival of 16.6 months and median overall survival of 27.0 months. Oncolytics has said it aligned with the FDA on the concept of a potential pivotal Part B expansion, with a proposed accelerated approval path based on response rate and progression-free survival as the basis for potential full approval. Pelareorep holds FDA Fast Track designation in colorectal, anal and pancreatic cancer and has been administered to more than 1,200 patients. "Given the current pace of enrollment, we expect to have the ability to report interim data from Part A by year-end," said John McAdory, Chief Operating Officer. The company has also been adding scientific support around the program. In September it reported preclinical results combining pelareorep with a pan-RAS inhibitor in a RAS-driven colorectal cancer model, in which the combination showed no evidence of antagonism, and it announced a peer-reviewed publication in the Proceedings of the National Academy of Sciences showing that pelareorep changed the liver tumor microenvironment from immunologically inactive to active in preclinical models. CONTINUED... Read more oncology sector coverage at: Equity Insider In other industry developments and happenings in the market this week include: Revolution Medicines, Inc. (NASDAQ: RVMD) Revolution Medicines announced on August 26 that the FDA approved RASONQUE (daraxonrasib), a once-daily oral tablet, for adults with metastatic pancreatic cancer who have received at least one prior systemic therapy or cannot receive multiagent therapy. In the Phase 3 RASolute 302 trial, median overall survival was 13.2 months with daraxonrasib versus 6.7 months with chemotherapy. The company has said it expects to share updated colorectal cancer data and strategy in the fourth quarter of 2026. "The FDA approval of RASONQUE is a monumental step forward for patients with pancreatic cancer and for the oncology field," said Mark A. Goldsmith, M.D., Ph.D., Chief Executive Officer and Chairman. Eli Lilly and Company (NYSE: LLY) Lilly announced on October 2 that the FDA approved Jaypirca (pirtobrutinib) for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma without a known 17p deletion. In the BRUIN CLL-313 trial, Jaypirca reduced the risk of progression or death by 80% compared with bendamustine plus rituximab, with an overall response rate of 94% versus 81%. Genmab A/S (NASDAQ: GMAB) Genmab and AbbVie announced on October 5 that the Phase 3 EPCORE DLBCL-2 trial of epcoritamab plus R-CHOP met its primary endpoint in newly diagnosed diffuse large B-cell lymphoma, reducing the risk of progression or death by 51% compared with R-CHOP alone. The companies plan to present the data at a future medical meeting and to engage with global regulators. Exelixis, Inc. (NASDAQ: EXEL) Exelixis disclosed that the FDA extended its review of zanzalintinib in combination with atezolizumab for metastatic colorectal cancer by three months after the company submitted updated safety and efficacy information, which the agency classed as a major amendment. The new target action date is March 3, 2027. Know Which Biotech Names Are Moving First Clinical readouts and FDA decisions can reprice a stock in minutes. Eagle Eye is a real-time investor signal-intelligence platform that surfaces sentiment shifts, news flow and trending tickers as they form, so you see attention building instead of chasing it. Watch it live at eagle-eye.dev. Contact Information: Equity Insider Media Contact: [email protected] DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a market commentary and is not a paid advertisement. It is neither an offer nor a recommendation to buy or sell any security. This article is being distributed by Equity Insider, which is wholly owned and operated by Market Equities Limited ("MEL"), a company incorporated under the laws of Ireland. This is an independent market commentary published on a non-paid basis. MEL has not been paid any fee by any company mentioned in this article for its production or distribution. MEL was previously paid a fee by Oncolytics Biotech, Inc. for advertising and digital media services under an arrangement that has since expired. MEL and/or its owners, operators, directors, and affiliates own shares of Oncolytics Biotech, Inc. purchased in the open market, and reserve the right to buy and sell shares of Oncolytics Biotech, Inc. at any time without any further notice. The prior compensation and this share ownership constitute a conflict of interest as to our ability to remain objective in our communication regarding Oncolytics Biotech, Inc. Because of this conflict, individuals are strongly encouraged not to use this publication as the basis for any investment decision. There may also be third parties who hold shares of Oncolytics Biotech, Inc. and may liquidate their shares, which could have a negative effect on the price of the stock. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this publication is not trustworthy unless verified by their own independent research. Because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Clinical results described in this article are as reported by each company; results from different studies are not directly comparable, and early-stage, preclinical and non-randomized data may not be confirmed in later trials. Be extremely careful: investing in securities carries a high degree of risk, and you may lose some or all of your investment. This document is governed by the laws of Ireland. Eagle Eye Disclosure. Eagle Eye is an investor signal-intelligence platform affiliated with the publisher of this article, and this reference constitutes promotion of an affiliated product. Eagle Eye is not a broker-dealer, and nothing in the platform or in this article is financial, investment, tax, or legal advice. Data provided in the platform is for informational purposes only and may be delayed. Always do your own research before making any investment decision. Forward-Looking Statements: This article may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements made by the companies mentioned in their own news releases. Such statements involve risks and uncertainties, and actual results may differ materially. Readers should review each company's filings with the SEC. SOURCE Equity Insider 21% more press release views with Request a Demo

01 项目名称 LB1410联合仑伐替尼加或不加LB4330对比研究者选择的化疗在晚期复发/转移性宫颈癌患者的有效性和安全性的多中心、随机、开放的Ⅱ/Ⅲ期临床研究 项目分期：Ⅱ/Ⅲ期 登记号：CTR20253433 02 适应症 经组织学确诊为宫颈鳞状细胞癌、宫颈腺鳞癌或HPV相关型宫颈腺癌(含LB4330队列可入组组织学确诊为宫颈胃型腺癌的患者)的复发性或转移性宫颈癌。 03 研究用药 药物名称：LB1410 药物介绍： LB1410是健信生物自主研发具有知识产权的基于帕博利珠单抗Keytruda(K药)序列升级的重组人源化抗PD-1/TIM-3双特异性抗体(BsAb)，拟用于经免疫治疗，放化疗或靶向治疗后耐药的肾癌、宫颈癌、肝癌等晚期恶性肿瘤。LB1410保持正常K药活性的基础上同时附加了TIM-3通路的阻断活性。一方面解除PD-1和TIM-3双信号通路介导的免疫抑制(T细胞耗竭)，恢复T细胞的肿瘤杀伤活性；另一方面，LB1410可在DC和T细胞之间形成桥联，促进T细胞抗肿瘤免疫反应。2026年美国临床肿瘤学会(ASCO)年会公布的Ⅰ期研究数据显示，LB1410单药总体安全性良好，3级及以上治疗相关不良事件发生率较低(约10.6%)，未观察到剂量限制性毒性；在既往抗PD-1/抗PD-L1治疗失败的宫颈癌患者中，客观缓解率(ORR)为38.5%，其中1例达到完全缓解(该患者既往已接受5线治疗，包括PD-1/CTLA-4双特异性抗体)；疾病控制率(DCR)达69.2%，中位无进展生存期(mPFS)达7.5个月，明显高于同类免疫耐药人群约6%的标准治疗有效率。部分有效患者目前仍在持续给药，最长给药时间已接近2年。 04 入选标准 ， 1.经组织学确诊为宫颈鳞状细胞癌、宫颈腺鳞癌或HPV相关型宫颈腺癌；含LB4330队列可入组组织学确诊为宫颈胃型腺癌的患者。 2.宫颈鳞状细胞癌、宫颈腺鳞癌和HPV相关型宫颈腺癌患者需满足，经标准治疗之后发生疾病进展或不可耐受毒性的复发性或转移性宫颈癌，复发或转移阶段治疗线数不超过3线，且满足2-a或2-b；a.受试者既往接受的宫颈癌治疗方案中有且仅有一个治疗线数包含抗PD-1/抗PD-L1治疗(针对FIGO2014III-IVA期宫颈癌患者的抗PD-1/抗PD-L1治疗算作一个线数的抗PD-1/抗PD-L1治疗，抗PD-1/抗PD-L1治疗后需进展)；至少接受4周期抗PD-1/抗PD-L1治疗且治疗期间18周内无影像学进展；b.受试者既往未经已知抗PD-1/抗PD-L1治疗但参加过含抗PD-1/抗PD-L1研究药物的双盲临床研究，且研究期间发生过典型的免疫检查点抑制剂相关的irAE(研究者判定与临床试验研究用药可能有关)；在此临床研究中至少接受4周期治疗且18周内无影像学进展(在获得确切的盲底信息前，该部分受试者的疗效数据作为有效性分析集EAS的独立部分，单独统计分析)；c.宫颈胃型腺癌复发或转移阶段既往未经免疫治疗，既往治疗线数不超过2线。 3.筛选时至少有1个根据RECISTv1.1标准评估的可测量病灶。 4.签署知情同意书时，年龄至少18周岁(含)。 5.东部肿瘤协作组(ECOG)体能状态0或1，在过去2周内无恶化。 6.研究者评估预期生存时间≥12周。 7.按下列定义，有充足的血液学功能：a.中性粒细胞绝对计数(ANC)≥1.5×109/L，研究治疗前2周内(≤14天)未使用粒细胞集落刺激因子，如非格司亭；b.血小板计数≥90×109/L，在研究治疗前2周内(≤14天)未输血或应用重组人血小板生成素等药物。联合LB4330的受试者，要求血小板计数≥120×109/L；c.血红蛋白≥90g/L，研究治疗前2周内(≤14天)未输血或未应用促红细胞生成素等药物。 8.AST和ALT均≤3×ULN(如果已知患者有肝转移，则AST和ALT<5×ULN)；总胆红素≤1.5×ULN(因已被记录的基础疾病Gilbert综合征或家族性良性非结合型高胆红素血症导致的血清胆红素升高者除外)；且血清白蛋白≥30g/L。 9.充分的肾功能，血清肌酐≤1.5×ULN；当血清肌酐≥1.5×ULN时，肌酐清除率≥40mL/min(通过Cockcroft-Gault公式)。 10.凝血功能要求如下：a.活化部分凝血活酶时间(APTT)≤1.5×ULN；b.国际标准化比值(INR)≤1.5×ULN(除外正在接受华法林抗凝治疗的患者，对于其INR要求为≤3×ULN)。 11.筛选期IL-6检测水平低于40pg/mL。 12.在采用或不采用抗高血压药物的情况下血压(BP)控制充分，定义为BP≤150/90mmHg并且在入组之前1周内抗高血压药物保持不变；不含仑伐替尼的队列要求BP≤160/100mmHg。 13.开始研究用药前既往抗肿瘤治疗的洗脱期(包括内分泌/放化疗/靶向治疗/免疫治疗等)：a.上一次细胞毒性化疗、免疫治疗或生物制剂治疗至少洗脱3周；b.既往激素治疗、小分子靶向药物至少洗脱2周；c.以抗肿瘤为适应症的中药至少洗脱2周；d.任何放疗至少洗脱2周；e.任何相关毒性或既往AE已恢复至基线或≤1级NCICTCAE5.0(研究者判断无安全风险的毒性除外，如脱发、2级外周神经毒性、经激素替代治疗稳定的内分泌异常等)。 14.育龄期女性必须同意在签署知情同意后、研究期间及研究药物最后一次给药后6个月内，采取有效的避孕措施。 15.患者能够理解并自愿签署知情同意书。16.患者能够并愿意遵守预定的访视、治疗计划、实验室检查和其他与研究相关的程序。 05 排除标准 ，1. 同时患双原发性肿瘤者（仅适用于队列 3）； 1.包含仑伐替尼队列，受试者满足下述任一条件则无资格参与本研究：a.影像学(CT或MRI)显示肿瘤已侵犯重要血管周或经研究者判断在后续研究期间肿瘤极有可能侵袭重要血管而引起致命大出血者；b.患有出血(如有临床意义的血尿、呕血、咯血等)、凝血性疾病或正在使用华法林、阿司匹林及其他抗血小板凝集药物者(阿司匹林≤100mg/d预防性用药除外)c.尿蛋白≥2+，且24小时尿蛋白定量≥1.0g。d.具有影响口服药物的多种因素(比如无法吞咽、胃肠道切除术后、慢性腹泻和肠梗阻等)可能影响仑伐替尼口服吸收者；e.肿瘤发生肠转移者或现有≥3级胃肠道或非胃肠道瘘管者；f.既往出现高血压危象或高血压脑病者。 2.妊娠或哺乳期女性。 3.诊断为宫颈小细胞(神经内分泌)癌、肉瘤或粘液性腺癌、透明细胞型腺癌及其他特殊类型的腺癌者。 4.既往免疫治疗中发生过≥3级免疫相关AE(irAEs)(激素替代治疗可控制的3级内分泌异常除外)。 5.患有活动性自身免疫性疾病或有症状的自身免疫性疾病病史(包括乳糜泻)需要使用全身性皮质类固醇和/或免疫抑制剂药理学剂量者。除外与医学监查员和申办方讨论后的以下情况：白癜风、已缓解的哮喘/特应性疾病、可通过替代疗法治疗且筛选期达到临床稳定的1型糖尿病或甲状腺功能减退症患者或任何其他自身免疫性疾病。 6.在计划的研究药物首次给药前14天内，需要接受全身性皮质类固醇(≥10mg/天泼尼松或等效药物)或其他免疫抑制药物治疗的患者。无活动性自身免疫性疾病的情况下，允许吸入或外用给药类固醇和肾上腺替代类固醇(泼尼松≤15mg每日一次当量)。允许眼用、鼻用、吸入和关节内注射应用类固醇；允许短期使用糖皮质激素进行预防治疗(如预防造影剂过敏)。 7.有以下任一既往治疗：a.首次给药前4周内接受过大型外科手术(如：剖腹术、开胸术、脏器切除术等)、发生严重创伤等(对于置换静脉输液滴管是可以接受的)；尚未从既往手术中完全恢复；首次给药前14天内接受过改善肿瘤并发症或减少肿瘤并发症风险的手术(如：宫颈癌受试者进行肾造瘘术或尿道支架置入术等)；计划在首次给药后的30天内(由研究者决定)进行重大外科手术者；b.研究药物首次给药前4周内使用过活疫苗或减毒活疫苗。c.研究药物首次给药前14天内使用过免疫调节药物，包括但不限于胸腺肽、白介素-2、干扰素等。d.有异体器官移植、异体外周造血干细胞移植或骨髓移植史。 8.HIV检测阳性者，活动性梅毒，有活动性乙型肝炎病毒感染、活动性丙型肝炎病毒感染者；注：如果HBsAg(+)和/或HBcAb(+)，则需检测HBV-DNA，结果必须<500IU/mL或<2500copies/mL或<正常值上限(ULN)方可入组。如HCV抗体(+)，则必须检测HCV-RNA，结果需<正常值上限(ULN)方可入组。允许纳入接受除干扰素外的抗病毒治疗的患者。 9.过去3年内患过其他恶性肿瘤(除外已治愈的皮肤基底细胞癌或鳞状细胞癌、乳腺或宫颈原位癌浅表性或非浸润性膀胱癌)。 10.存在脑膜转移、脊髓压迫，有症状或入组前4周需要类固醇和/或抗癫痫药物治疗的不稳定脑转移。 11.首次给药前14天内任何需要接受全身治疗的活动性感染。 12.未控制或控制不佳的糖尿病、哮喘、慢性阻塞性肺病，或对参与研究患者构成风险的其他疾病。 13.6个月内发生过动/静脉血栓事件，包括脑血管意外(如短暂性脑缺血、脑出血、包括腔隙性脑梗塞等脑梗塞)、深静脉血栓及肺栓塞等。 14.伴有临床症状且不稳定的胸腔积液或腹腔积液或心包积液者；接受过胸膜腔内灌注治疗的患者，需在胸水稳定后14天及以上入组。 15.有膀胱阴道瘘、结肠阴道瘘或直肠阴道瘘现病史。 16.首次给药之前28天出现任何晕厥或癫痫发作。 17.心血管功能障碍或有临床意义的心血管疾病，包括但不限于以下：#研究之前3个月内未能控制的心血管疾病(包括但不限于需要治疗的充血性心力衰竭(NYHA>Ⅱ级)、未良好控制的心律失常)；#近6个月内的心肌梗死、不稳定型的心绞痛、病毒性心肌炎、心包炎、脑血管意外或其他急性未控制的心脏病。#心电图检查QTcF>470毫秒(QTcF=QT/RR1/3，若首次QTcF≥470毫秒，可再连续检查2次心电图取3次QTcF中位数)，或先天性长QT综合征。#心脏彩超评估：左室射血分数(LVEF)≤50%(通过多门控采集(MUGA)或超声心动图测量的)。 18.已知存在间质性肺病，该病有症状或可能妨碍可疑的与药物相关肺毒性的发现或管理，放化疗引起的且目前没有症状的间质性肺病除外。 19.已知存在活动性肺结核(TB)。怀疑有活动性TB的受试者，研究者需完善相关检查排除诊断。 20.伴有累及中枢神经系统的疾病(除外首次给药前至少4周治疗的、临床稳定且不需要接受长期皮质类固醇治疗的既往脑转移患者)，或有NCICTCAE5.0评估标准3级及以上药物相关的中枢神经系统毒性既往史。 21.已知对其他单克隆抗体或静脉注射丙种球蛋白产生严重超敏反应的病史；或已知对抗PD-1/抗PD-L1抗体、TIM-3、白介素-10或其任何辅料成份有过敏或超敏反应史者。 22.既往使用过本研究同等机理的药物(如：PD1单抗联合TIM3单抗、PD1和TIM3双特异抗体)，除外单独用过PD-1/PD-L1单抗或TIM3单抗。 23.患有严重精神障碍史、药物滥用史、吸毒史或酗酒者。 24.有任何其他疾病(包括严重医学或精神疾病/状况)或发生具有显著临床意义的实验室指标异常时，研究者判断可能影响受试者安全性、研究的完整性或受试者参与研究。25.(仅限含LB4330队列)既往2年内任何抗肿瘤治疗中发生过血小板相关的IV度骨髓抑制或既往使用过含IL-10成分的药物。 06 研究中心 研究机构 向上滑动阅览 报名方式 参与临床试验，获取前沿新药新疗法使用机会！更有一线专家团队为你的治疗保驾护航！ 【海普洛斯患者招募】目前有肺癌、黑色素瘤、胃癌、肠癌、食管癌、胰腺癌、乳腺癌、肝癌、宫颈癌、卵巢癌、胶质母细胞瘤、白血病……等几乎涵盖所有癌种的临床试验正在招募患者！ 注：此项目为临床试验项目，具体开展时间、补助等详情，请以研究中心通知和知情同意书为准，更多项目请关注“海普洛斯招募”小程序。   招募合集 【Ⅰ期临床试验招募】TAVO412 晚期/转移性实体瘤 【Ⅱ期临床试验招募】马来酸氟诺替尼片中高危骨髓纤维化治疗 【Ⅲ期临床试验招募】EGFR！SH-1028片II-IIIB期非小细胞肺癌辅助治疗 【III期临床试验招募】安进已上市靶向药Sotorasib联合化疗招募初治PD-L1阴性且KRAS G12C阳性肺癌 【III期临床试验招募】默沙东ADC药物MK-2870联合帕博利珠单抗招募初治PD-L1高表达非小细胞肺癌患者 患者招募|Tiragolumab 联合阿替利珠单抗和贝伐珠单抗用于晚期PD-L1 阳性非鳞非小细胞肺癌治疗 患者招募 | 帕博利珠单抗联合或不联合 MK-2870 治疗未达到 pCR 的可切除 NSCLC 受试者 患者招募 | 纳武利尤单抗+ LAG3抑制剂的复合物联合化疗治疗晚期NSCLC的研究 患者招募 | 帕博利珠单抗（MK-3475）对比化疗治疗MSI-H或dMMR的IV期结直肠癌患者 患者招募 | 辉瑞（SGN - B6A)对比多西他赛治疗经治的非小细胞肺癌患者 患者招募 | 重组溶瘤腺病毒注射剂（KD01）瘤内给药治疗晚期实体瘤患者 患者招募 | Trastuzumab Deruxtecan治疗HER2过表达肿瘤患者患者 患者招募 | BAY 2927088一线治疗携带 HER2 突变的不可切除、局部晚期或转移性非小细胞肺癌患者 黑色素瘤患者招募 | 妥拉美替尼治疗既往接受过免疫治疗的NRAS突变的晚期黑色素瘤患者 实体瘤患者招募 | BAY 2927088治疗携带 HER2 激活突变的不可切除或转移性实体瘤成人患者 肌无力患者招募 | SYS6020注射液治疗难治性全身型重症肌无力患者 患者招募 | RX208(HLX208)治疗晚期黑色素瘤患者 患者招募 | HS-IT101注射液治疗晚期黑色素瘤患者 患者招募  |  注射用FZ-AD005抗体偶联剂在晚期实体瘤患者 患者招募 | 治疗EGFR罕见突变晚期非小细胞肺癌患者 患者招募 | 治疗复发/进展性胶质母细胞瘤患者 患者招募 | 治疗不可切除的转移性结直肠癌患者 患者招募 | 治疗局部晚期或转移性乳腺癌患者 患者招募 | 治疗晚期/转移性实体瘤患者 【III期临床试验招募】QL1706注射液联合贝伐珠单抗及XELOX对比方案一线治疗不可切除的转移性结直肠癌患者 【III期临床试验招募】IBI343治疗Claudin(CLDN)18.2阳性的局部晚期不可切除或转移性胰腺癌患者 患者招募 | 治疗ROS1阳性局部晚期或转移性非小细胞肺癌患者 【I期临床试验招募】评估SSGJ-612在晚期实体瘤受试者中的安全性 【Ⅲ期临床试验招募】SKB264联合帕博利珠单抗对比化疗一线治疗PD-L1阴性局部非鳞状非小细胞肺癌患者临床研究 【I期临床试验招募】9MW2821单药或联合治疗宫颈癌/尿路上皮癌的Ib/II期研究 【临床试验招募】BAT8006联合贝伐珠单抗对比贝伐珠单抗单药用于铂敏感复发性卵巢癌患者维持治疗的临床研究 【Ⅲ期临床试验招募】ROS1 阳性局部晚期或转移性非小细胞肺癌中 Taletrectinib 与标准治疗的研究 注射用LB1410在肝癌及宫颈癌患者中的临床研究 【II期临床试验招募】评价伯瑞替尼联合PLB1004一线治疗EGFR突变伴MET异常的局部晚期或转移性非小细胞肺癌患者的临床研究 【临床试验招募】评价QL1706围手术期治疗可切除结肠癌的临床研究 【临床试验招募】LBL-024单药、LBL-024联合LBL-007或特瑞普利单抗治疗晚期黑色素瘤患者的临床研究 海普洛斯患者招募平台首发上线！SSGJ-706临床项目同步开放，即刻申请，一键匹配 【临床试验招募】 ROS1 阳性局部晚期或转移性非小细胞肺癌中 Taletrectinib 与标准治疗的 III 期比较研究 【临床试验招募】 评价妥拉美替尼胶囊对比化疗治疗NRAS突变晚期黑色素瘤—— 一项面向既往免疫治疗失败患者的III期研究 【临床试验招募】 化疗一线治疗 MSI-H/dMMR 转移性结直肠癌的 III 期临床研究试验 【临床试验招募】控制不佳的重度哮喘患者的 III 期临床试验 【临床试验招募】NTRK基因异常的局部晚期/转移性成人实体瘤受试者中的 1/2 期临床研究 【临床试验招募】铂耐药复发上皮性卵巢癌、原发性腹膜癌或输卵管癌的 III 期临床研究 【临床试验招募】KRAS G12D 突变型晚期实体瘤患者的 I/II 期临床研究 【临床试验招募】ETX-636 在晚期实体瘤患者中的 1/2 期开放性研究 【临床试验招募】SYS6043 在晚期/转移性实体瘤患者中的安全性、耐受性、药代动力学和有效性的临床研究 【临床试验招募】一项评估试验药物治疗系统性红斑狼疮的临床研究 【临床试验招募】AFN50治疗自身免疫性疾病的临床研究 【临床试验招募】注射用 TQB6411 治疗晚期肺癌的 Ib/II 期研究 【临床试验招募】注射用 TQB6411 治疗食管癌的 Ib/II 期临床试验 【临床试验招募】TLL-018治疗中重度特应性皮炎的临床研究 【临床试验招募】TQB6411 在 PD-1/PD-L1 单抗联合含铂化疗失败的复发/转移性食管鳞癌中的 Ib/II 期临床研究 【临床试验招募】SCTB14对比帕博利珠单抗一线治疗驱动基因阴性、TPS≥10%的局部晚期或转移性非小细胞肺癌的Ⅲ期临床研究 END 关于海普洛斯       海普洛斯是肿瘤液体活检和基因大数据国家高新技术企业，在基因测序、液体活检、生命信息和大数据等领域具有核心技术优势，以科技创新造福人类，致力于成为全球领先的生命科技公司。       旗下医学检验实验室配有先进的基因测序平台以及建立了完善的质量管理体系，已连续通过CAP(美国病理学家协会)、EMQN(欧洲分子基因诊断质量联盟)、NCCL(国家卫生健康委临床检验中心)、PQCC(国家病理质控中心)等国内外权威机构组织的室间质评400+次，并荣获CAP、CLIA(美国临床实验室改进法案修正案)国际权威质量认证。业务覆盖肿瘤全病程管理、遗传性疾病筛查、重大感染性疾病筛查等领域，已为全国数百家三甲医院、科研院所、体检机构、保险公司以及各地政府提供基因检测技术服务和整体解决方案。